GlaxoSmithKline (GSK) will partner with VBI Vaccines to study VBI’s LPV™ Platform, a formulation and process designed to help develop vaccines and biologics with improved stability and potency. The ...
Sanofi Pasteur has chosen VBI's LPV™ technology to develop a more stable formulation of a key Sanofi Pasteur vaccine candidate. The collaboration will leverage VBI's LPV™ technology, which allows for ...
Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's (FDA) tentative ...
Infants and young children living with HIV will finally have access to an improved formulation of an antiretroviral (ARV) treatment, following the U.S. Food and Drug Administration's (FDA) tentative ...
Children living with HIV have to take multiple different antiretroviral (ARV) pills or syrups twice a day, while most adults in South Africa have been offered one pill once a day regimen for around a ...
The US FDA has approved an innovative formulation, Lopinavir/ritonavir (LPV/r) 40mg/10mg oral pellets, for paediatric specific treatment of HIV/Aids in infants. Cipla Medpro CEO, Paul Miller Developed ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
Under the terms of the research collaboration, GSK has the option to negotiate an exclusive license to VBI’s LPV Platform for use in a defined field. Further terms of the collaboration were not ...
Licence will support the work of the recently launched Paediatric HIV Treatment Initiative (PHTI) to Develop Better Adapted Medicines for Children Living with the Virus GENEVA, December 1, 2014 – On ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results